Бастиан Блоэм - Нестареющее тело. Научное исследование о том, как защитить свои тело и мозг и не допустить развития неврологических заболеваний

22. Limousin P, Foltynie T. Long-term outcomes of deep brain stimulation in Parkinson disease. Nature Reviews Neurology. 2019;15(4):234–242.

23. Medtronic Activa Tremor Control System. US Food and Drug Administration. Premarket Approval (PMA). www.accessdata.fda.gov/ scripts/cdrh/cfdocs/cfPMA/pma.cfm?id=P960009. Updated March 25,

2019. Accessed March 29, 2019.

24. Rossi PJ, Giordano J, Okun MS. The problem of funding off-label deep brain stimulation: bait-and-switch tactics and the need for policy reform. JAMA Neurology. 2017;74(1):9-10; Abosch A, Timmermann L, Bartley S, et al. An international survey of deep brain stimulation procedural steps. Stereotactic and Functional Neurosurgery. 2013;91(1):1-11.

25. Eberle W, Penders J, Yazicioglu RF. Closing the loop for deep brain stimulation implants enables personalized healthcare for Parkinson’s disease patients. Paper presented at the 2011 Annual International Conference of the IEEE Engineering in Medicine and Biology Society, August 30-September 3, 2011; Patel S, Mancinelli C, Hughes R, Dalton A, Shih L, Bonato P. Optimizing deep brain stimulation settings using wearable sensing technology. Paper presented at the 2009 4th International IEEE/EMBS Conference on Neural Engineering, April 29May 2, 2009.

26. Anidi C, O’Day JJ, Anderson RW, et al. Neuromodulation targets pathological not physiological beta bursts during gait in Parkinson’s disease. Neurobiology of Disease. 2018;120:107–117; Malekmohammadi M, Herron J, Velisar A, et al. Kinematic adaptive deep brain stimulation for resting tremor in Parkinson’s disease. Movement Disorders . 2016;31(3):426–428.

27. Parker KL, Kim Y, Alberico SL, Emmons EB, Narayanan NS. Optogenetic approaches to evaluate striatal function in animal models of Parkinson disease. Dialogues in Clinical Neuroscience. 2016;18(1):99-107.

28. Henderson R. The purple membrane from Halobacterium halobium. Annual Review of Biophysics and Bioengineering. 1977;6:87-109.

29. Там же.

30. Parker KL, Kim Y, Alberico SL, Emmons EB, Narayanan NS. Optogenetic approaches to evaluate striatal function in animal models of Parkinson disease. Dialogues in Clinical Neuroscience. 2016;18(1):99-107.

31. Там же.; Fenno L, Yizhar O, Deisseroth K. The development and application of optogenetics. Annual Review of Neuroscience. 2011;34(1):389–412.

32. Kravitz AV, Freeze BS, Parker PRL, et al. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature. 2010;466(7306):622–626.

33. Там же.

34. Там же.

35. Alessi DR, Sammler E. LRRK2 kinase in Parkinson’s disease. Science. 2018;360(6384):36–37.

36. Там же.

37. Denali Therapeutics announces positive clinical results from LRRK2 inhibitor program for Parkinson’s disease. Denali Therapeutics. August 1, 2018. http://investors.denalitherapeutics. com/ news-releases/ news-release-details/denali-therapeutics-announces-positive-clinical-results-lrrk2#ir-pages. Accessed November 29, 2018.

38. Denali Therapeutics announces first patient dosed in phase 1B study of DNL201 for Parkinson’s disease [пресс-релиз]. Denali Therapeutics, December 10, 2018; Study to evaluate DNL201 in subjects with Parkinson’s disease. US National Library of Medicine: ClinicalTrials. gov. https://clinicaltrials.gov/ct2/show/NCT03710707. Updated March 28, 2019. Accessed March 29, 2019.

39. Tracking LRRK2-Parkinson’s progression for better trial design. Alzforum. March 23, 2018. www.alzforum.org/news/research-news/ tracking-lrrk2-parkinsons-progression-better-trial-design. Accessed November 30, 2018.

40. Alessi DR, Sammler E. LRRK2 kinase in Parkinson’s disease. Science . 2018;360(6384):36–37.

41. Там же.; Stott S. New LRRK2 results: game changer? Science of Parkinson’s. July 25, 2018. https://scienceofparkinsons.com/2018/07/25/lrrk-2. Accessed June 27, 2019; Di Maio R, Hoffman EK, Rocha EM, et al. LRRK2 activation in idiopathic Parkinson’s disease. Science Translational Medicine. 2018;10(451).

42. Di Maio R, Hoffman EK, Rocha EM, et al. LRRK2 activation in idiopathic Parkinson’s disease. Science Translational Medicine. 2018;10(451).

43. Goker-Alpan O, Schiffmann R, LaMarca ME, Nussbaum RL, Mc Inerney-Leo A, Sidransky E. Parkinsonism among Gaucher disease carriers. Journal of Medical Genetics. 2004;41(12):937–940.

44. Klein C, Westenberger A. Genetics of Parkinson’s disease. Cold Spring Harbor Perspectives in Medicine. 2012;2(1):a008888; Alcalay RN, Caccappolo E, Mejia-Santana H, et al. Frequency of known mutations in earlyonset Parkinson disease: implication for genetic counseling: the Consortium on Risk for Early-Onset Parkinson Disease study. Archives of Neurology. 2010;67(9):1116–1122.

45. Sidransky E, Lopez G. The link between the GBA gene and parkinsonism. Lancet Neurology. 2012;11(11):986–998.

46. Velayati A, Yu WH, Sidransky E. The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. Current Neurology and Neuroscience Reports. 2010;10(3):190–198.

47. Konrad A. Meet the top VC in a race to find his own Parkinson’s cure. Forbes. April 18, 2017. www.forbes.com/sites/alexkonrad/2017/04/18/ jonathan-silverstein-venturing-for-a-cure/#4d17b6ba50a3. Accessed June 27, 2019.

48. The Silverstein Foundation in the News. Silverstein Foundation for Parkinson’s with GBA. www.silversteinfoundation.org/in-the-news. Accessed March 29, 2019.

49. On the money. CNBC. August 19, 2017. https://archive.org/details/ CNBC_20170819_ 093000_On_the_Money.

50. Silverstein Foundation for Parkinson’s with GBA. 2018. www. silversteinfoundation.org. Accessed November 30, 2018.

51. Konrad A. Meet the top VC in a race to find his own Parkinson’s cure. Forbes. April 18, 2017. www.forbes.com/sites/alexkonrad/2017/04/18/ jonathan-silverstein-venturing-for-a-cure/#4d17b6ba50a3. Accessed June 27, 2019.

52. About Prevail. Prevail Therapeutics. www.prevailtherapeutics.com/ about-prevail. Accessed November 30, 2018.

53. Silveira CRA, MacKinley J, Coleman K, et al. Ambroxol as a novel disease-modifying treatment for Parkinson’s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial. BMC Neurology. 2019;19(1):20–20; McNeill A, Magalhaes J, Shen C, et al. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain. 2014; 137(5): 1481–1495; Sardi SP, Cedarbaum JM, Brundin P. Targeted therapies for Parkinson’s disease: from genetics to the clinic. Movement Disorders. 2018;33(5):684–696.

54. Kuhl MM. First trial begins testing drug in people with GBA mutation. FoxFeed Blog. February 14, 2017. www.michaeljfox.org/news/first-trial-begins-testing-drug-people-gba-mutation. Accessed June 27, 2019.

55. Там же.; Sanofi initiates phase 2 clinical trial to evaluate therapy for genetic form of Parkinson’s disease [пресс-релиз]. Business Wire. February 14, 2017. www.businesswire.com/ news/home/20170214005771/en/ Sanofi-Initiates-Phase-2-Clinical-Trial-Evaluate. Accessed June 27, 2019; A global study to assess the drug dynamics, efficacy, and safety of GZ/ SAR402671 in Parkinson’s disease patients carrying a glucocerebrosidase (GBA) gene mutation (MOVES-PD). US National Library of Medicine: ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/ NCT02906020. Updated March 14, 2019. Accessed March 29, 2019; Sardi SP, Viel C, Clarke J, et al. Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models. Proceedings of the National Academy of Sciences of the United States of America. 2017;114(10):2699–2704.